American Academy of Ophthalmology Meeting
American Academy of Ophthalmology Meeting
October 14, 2016
2 min watch

VIDEO: Sun Ophthalmics poised to launch BromSite, Xelpros

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

CHICAGO — At the Ophthalmology Innovation Summit here Jerry St. Peter, vice president and head of Sun Ophthalmics, discusses the intended November launch of BromSite (bromfenac ophthalmic solution 0.075%), a nonsteroidal anti-inflammatory drug that has been FDA-approved for prevention of ocular pain and treatment of postoperative inflammation in patients undergoing cataract surgery. As well, St. Peter anticipates the future launch of Xelpros (0.005% latanoprost) for the treatment of glaucoma.